LODOSYN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LODOSYN (LODOSYN).
Lodosyn (carbidopa) is a peripheral decarboxylase inhibitor that inhibits the conversion of levodopa to dopamine outside the central nervous system. By blocking aromatic L-amino acid decarboxylase (AAAD) in peripheral tissues, it increases the amount of levodopa available to cross the blood-brain barrier, enhancing central dopamine levels and reducing peripheral side effects such as nausea and vomiting.
| Metabolism | Carbidopa is metabolized primarily via conjugation (glucuronidation) and oxidation, with 50-60% of the dose excreted unchanged in urine. The major metabolite is 3-O-methylcarbidopa, formed by catechol-O-methyltransferase (COMT). |
| Excretion | Renal: 70% unchanged; 30% as O-methylated and sulfate conjugates. Biliary/fecal: <5%. |
| Half-life | 1.5–2.5 hours in adults; prolonged in renal impairment (up to 6–8 hours). |
| Protein binding | 40–50%, primarily to albumin. |
| Volume of Distribution | 1.0–1.5 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral: 60–75% (first-pass metabolism). IV: 100%. |
| Onset of Action | Oral: 45–60 minutes; IV: 15–30 minutes. |
| Duration of Action | Oral: 4–6 hours; IV: 2–4 hours. Shorter with rapid renal clearance. |
| Molecular Weight | 226.23 |
250 mg orally twice daily, in combination with levodopa/carbidopa.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use caution with GFR <30 mL/min. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not established; off-label use not recommended. |
| Geriatric use | Start at lower end of dosing range; monitor for adverse effects. |
| 1st trimester | Carbidopa is not recommended during the first trimester due to lack of safety data; avoid use. |
| 2nd trimester | Limited data suggest potential risks; use only if clearly needed. |
| 3rd trimester | Use only if maternal benefit outweighs fetal risk; monitor for possible effects on fetal development. |
Clinical note
Comprehensive clinical and safety monograph for LODOSYN (LODOSYN).
| Placental transfer | Carbidopa crosses the placenta; fetal concentrations are likely lower than maternal but may still pose risk. |
| Breastfeeding | Carbidopa is excreted into breast milk in small amounts; due to potential for adverse effects in the infant, use during breastfeeding is generally not recommended. Consider alternative therapy. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to carbidopa or any componentConcurrent use of nonselective MAO inhibitors (e.g., phenelzine, tranylcypromine)Narrow-angle glaucomaSuspected melanoma or history of melanomaSevere hypertension or pheochromocytoma
| Precautions | Risk of neuroleptic malignant syndrome (NMS) upon abrupt withdrawal or dose reduction, May cause dyskinesias or psychiatric disturbances (e.g., hallucinations, depression) due to increased central dopamine, Must be used with levodopa; not effective alone, Caution in patients with cardiovascular disease, peptic ulcer disease, or glaucoma, May affect glucose tolerance; monitor diabetic patients, May cause false positive urine ketone tests |
| Food/Dietary | High-protein meals can reduce absorption of levodopa, so take LODOSYN with levodopa on an empty stomach or as directed. Avoid taking with iron supplements or multivitamins containing iron, as iron chelates with carbidopa and reduces effectiveness. Avoid foods high in pyridoxine (vitamin B6) in large amounts, as it may counteract levodopa effects unless carbidopa is present. |
Loading safety data…
| L4 - Possibly Hazardous |
| Teratogenic Risk | Lodosyn (carbidopa) is used in combination with levodopa. There are no adequate well-controlled studies in pregnant women. Animal reproduction studies have shown fetal abnormalities at high doses. The risk is likely minimal during first trimester, but potential benefits must outweigh risks. Second and third trimester risks are unknown; avoid use unless clearly necessary. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of dyskinesia. Fetal monitoring includes ultrasound for growth and development if prolonged use. No specific routine monitoring required outside standard prenatal care. |
| Fertility Effects | No specific human data on fertility. Animal studies have not shown significant effects. However, levodopa may affect prolactin levels, potentially impacting fertility. Use with caution in women planning pregnancy. |
| Clinical Pearls | LODOSYN (carbidopa) is a peripheral decarboxylase inhibitor used in combination with levodopa for Parkinson disease. It prevents the peripheral conversion of levodopa to dopamine, reducing side effects like nausea and increasing levodopa availability to the brain. Always assess for dyskinesias, motor fluctuations, and neuropsychiatric effects. Avoid abrupt discontinuation to prevent neuroleptic malignant syndrome. Monitor for melanoma risk and recommend periodic skin exams. |
| Patient Advice | Take this medication exactly as prescribed; do not stop suddenly without consulting your doctor. · May cause dizziness or drowsiness; avoid driving until you know how it affects you. · Report any unusual movements, mood changes, or dark urine to your healthcare provider. · Avoid high-protein meals when taking the medicine, as protein can reduce absorption. · Inform all healthcare providers that you are taking this drug, especially before surgery. |